Covidien plans another mammoth buy-back
This article was originally published in Clinica
Less than two years after launching a substantial $2 billion share repurchase programme, Covidien's board has authorised another $3 billion buy-back. The previous programme, started in August 2011 (www.clinica.co.uk, 12 August 2011), currently has around $425 million remaining, the firm said. Covidien is currently well above its stated annual goal of returning at least 50% of free cash flow to shareholders: in 2012, this totalled $1.75 billion, or nearly 100%.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.